Regentis Biomaterials Ltd (RGNT)
Regentis Biomaterials Ltd. is a healthcare company focused on regenerative medicine and tissue repair solutions. The company develops and commercializes products in the United States, including Gelrin, a hydrogel-based platform designed for the repair and regeneration of damaged or diseased tissue. Its pipeline also includes GelrinC, a cell-free, off-the-shelf hydrogel that is being evaluated in a Phase II clinical trial for cartilage injuries in the knee. Incorporated in 2004, Regentis Biomaterials is based in Herzliya, Israel, and its common stock is listed on the NYSE under the symbol RGNT.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-RGNT
|
$1.57
|
-13.2% Downside
|
Fair
|
$10
|
452.5% Upside
|
Bargain
|
Weak
|
0.0%
|
1.7x
|
12.713 M
|
3.79 M
|
0.2%
|
46.7%
|
-13.3
|
29.7%
|
